These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 33868488)

  • 1. Investigating Tobacco's Impact on DNA Repair Genes and Risks in Oral Precancer and Cancer: A Comprehensive Research Study.
    Mohammad S; Farooqui S; Srivastava S; Siang TC; Sridhar SB; Ahmad I; Alamri S
    J Maxillofac Oral Surg; 2024 Aug; 23(4):808-815. PubMed ID: 39118938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
    Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival association of XRCC1 for patients with head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang F; Zhou L; Chen J; Luo Y; Wang Y
    Front Genet; 2022; 13():1035910. PubMed ID: 36685969
    [No Abstract]   [Full Text] [Related]  

  • 4. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence.
    Wang YY; Fang PT; Su CW; Chen YK; Huang JJ; Huang MY; Yuan SF
    Oncol Lett; 2021 Jun; 21(6):450. PubMed ID: 33868488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
    Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
    World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix.
    Bajpai D; Banerjee A; Pathak S; Jain SK; Singh N
    Mol Cell Biochem; 2013 May; 377(1-2):45-53. PubMed ID: 23435956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
    CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of smoking and alcohol history in young age oral cavity cancer.
    Lee SU; Moon SH; Choi SW; Cho KH; Park JY; Jung YS; Ryu J; Ryu CH; Yun T; Kim TH; Youn SH; Oh ES
    Oral Dis; 2020 Oct; 26(7):1440-1448. PubMed ID: 32430951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.
    Huang RX; Zhou PK
    Signal Transduct Target Ther; 2020 May; 5(1):60. PubMed ID: 32355263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking History Decreases Survival in Patients with Squamous Cell Carcinoma of the Mouth: A Retrospective Study with 15 Years of Follow-up.
    Colares N; Souza Rodrigues DF; Freitas MO; Dantas TS; Cunha MDPSS; Sousa FB; Barros Silva PG
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1781-1787. PubMed ID: 31244300
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.